Research interests/description of main research theme:
Foxp3+CD25+CD4+ regulatory T cells (Treg) have been shown to be essential for the induction of tolerance to foreign organ transplants in experimental models. In addition, human in vitro-expanded Treg prevent the rejection of human skin and vessel transplants in humanised mice and are able to suppress graft versus host disease in human bone-marrow transplant recipients. Therefore, these studies suggest that Treg that have been expanded in vitro could be re-infused back into recipients to prevent organ rejection/graft versus host disease (GVHD) and autoimmunity.
Despite the promise of Treg as a cellular therapy, we believe that genetic manipulation of such cells prior to re-introduction into patients may allow Treg to be generated that demonstrate increased immunosuppressive potency in vivo. With this in mind, the project will explore the use of retroviral delivery of genes that may aid Treg localisation, survival, stability and function. The project will make use of existing retroviral gene transduction technologies and expertise at the University of Birmingham (Frumento et al, Am J Transplant. 2013. 13(1):45-55). In addition, the immunosuppressive potency of gene manipulated Treg will be compared to sham-transduced Treg in established in vitro T cell function assays and models of skin, heart and bone-marrow (to induce GVHD) transplantation.
This project will not only identify genes that may increase Treg function but will also inform on questions such as how long injected Treg survive, which tissue Treg home to and reside in (allograft/lymphoid tissue/non-lymphoid tissue) and whether a proportion of injected Treg re-differentiate into effector cells. These are all important questions that will need to be addressed prior to the routine clinical use of such cells. Excitingly, the opening of the new Cell Therapy Facility at the University of Birmingham will enable the translation of the findings of this and other contiguous studies through to the clinical arena.
Applicants should have a strong background in immunology, and ideally a background in T cell/Treg biology and immune-mediated disease/transplantation. They should have a commitment to research in Transplantation and/or autoimmunity and hold or realistically expect to obtain at least an Upper Second Class Honours Degree in a relevant subject.
How to apply
Informal enquiries should be directed to Nick Jones (www.birmingham.ac.uk/nick-jones)
Applications should be directed to Nick Jones (email [email protected]
). To apply, please send:
• A detailed CV, including your nationality and country of birth;
• Names and addresses of two referees;
• A covering letter highlighting your research experience/capabilities;
• Copies of your degree certificates with transcripts;
• Evidence of your proficiency in the English language, if applicable.
Yang, J., M.O. Brook, M. Carvalho-Gaspar, J. Zhang, H.E. Ramon, M.H. Sayegh, K.J. Wood, L.A. Turka, and N.D. Jones. 2007. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A 104:19954-19959.
Carvalho-Gaspar, M., N.D. Jones, S. Luo, L. Martin, M.O. Brook, and K.J. Wood. 2008. Location and time-dependent control of rejection by regulatory T cells culminates in a failure to generate memory T cells. J Immunol 180:6640-6648.
Jones, N.D., M.O. Brook, M. Carvalho-Gaspar, S. Luo, and K.J. Wood. 2010. Regulatory T cells can prevent memory CD8(+) T-cell-mediated rejection following polymorphonuclear cell depletion. Eur J Immunol 40:3107-3116.
Wood, K.J., A. Bushell, and N.D. Jones. 2011. Immunologic unresponsiveness to alloantigen in vivo: a role for regulatory T cells. Immunol Rev 241:119-132.
Kinnear, G., K.J. Wood, F. Fallah-Arani, and N.D. Jones. 2013. A Diametric Role for OX40 in the Response of Effector/Memory CD4+ T Cells and Regulatory T Cells to Alloantigen. J Immunol 191:1465-1475.